MCRB - Seres receives $125M milestone payment for FDA Approval of Vowst for C. difficile Infection
2023-05-30 16:26:43 ET
- Seres Therapeutics ( NASDAQ: MCRB ) said it received a $125M milestone payment from Nestlé Health Science following the FDA approval of Vowst for preventing recurrence of C. difficile Infection ( CDI ) in adults after antibiotic treatment for recurrent CDI.
- The milestone payment is part of the agreement between Seres and Nestlé Health to jointly commercialize Vowst in the U.S. and Canada.
- Both companies will equally share in commercial profits and losses once VOWST is commercialized.
- Seres is also eligible to receive up to $225M in payments for achieving specified net sales milestones .
- (MXRB) is up 2% after the bell.
For further details see:
Seres receives $125M milestone payment for FDA Approval of Vowst for C. difficile Infection